Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ABP-745 in Healthy Volunteers
NCT06258213Phase 1Completed
- Sponsor
- Atom Therapeutics
- Start
- Jan 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in gout comparing Placebo with ABP-745 (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events at Day 14. Started Jan 2024; status: completed.
02
Drugs
ABP-745
03
Conditions
gout
Beyond the preview
Go deeper on NCT06258213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258213.